Ann Rheum Dis. 2023;82(3):331–343 doi: 10.1136/ard-2022-222543
Results from the open-label, randomised controlled ORAL Surveillance trial find increased risk of malignancies with tofacitinib versus TNFi, highlighting the highest incidence in patients with a history of atherosclerotic cardiovascular disease or increasing cardiovascular risk.
Curtis, et al. characterise malignancy events and evaluate the potential associations of baseline risk factors and cardiovascular risk with malignancies, in a cardiovascular risk-enriched RA population from the ORAL Surveillance study. Their findings may assist in the assessment of the risk–benefit profile of tofacitinib, and help to inform treatment decisions for patients with RA who feature increased cardiovascular risk.